Tuberculosis: Cost of illness in Germany

European Respiratory Journal

Volumn 40, Issue 1, 2012, Pages 143-151

  Diel, Roland ^a   Rutz, Stefan ^b   Castell, Stefanie ^c   Schaberg, Tom ^d  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Barmer GEK Public Health Insurance ^*  (Germany)

^c German Central Committee Against Tuberculosis   (Germany)

^d Deaconess Hospital Rotenburg   (Germany)

Author keywords

Cost analysis; Diagnostic procedures; Guidelines; Multidrug resistant tuberculosis; Therapy

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN;

ARTICLE; BRONCHOSCOPY; COST BENEFIT ANALYSIS; DRUG INDUCED HEADACHE; EYE EXAMINATION; GASTROINTESTINAL DISEASE; GERMANY; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH STATISTICS; HOSPITAL PATIENT; HUMAN; INSOMNIA; LABORATORY TEST; LIVER DYSFUNCTION; MULTIDRUG RESISTANT TUBERCULOSIS; NEPHROTOXICITY; OPTIC NEURITIS; OUTCOME ASSESSMENT; OUTPATIENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRODUCTIVITY; PSYCHOSIS; TUBERCULOSIS; X RAY FILM;

ADULT; AMBULATORY CARE; ANTITUBERCULAR AGENTS; CHILD; COST OF ILLNESS; COSTS AND COST ANALYSIS; GERMANY; HEALTH CARE COSTS; HUMANS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84863490825     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00204611     Document Type: Article

References (38)

1. World Health Organization. Global tuberculosis control: WHO report 2011. Geneva, Switzerland, 2011.
2. World Health Organization. 2011/2012 Tuberculosis Global Facts. Geneva, Switzerland, 2011.
3. Diel R, Rappenhöner B, Schaberg T. The cost structure of lung tuberculosis in Germany. Eur J Health Econ 2004; 5: 243-251. (Pubitemid 39382523)
4. Robert Koch Institut. Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2009. [Report on the epidemiology of tuberculosis in Germany in 2009.] Berlin, 2011.
5. Kassenärztliche Bundesvereinigung, Einheitlicher Bewertungsmaßstab [EBM], Stand 1. October 2011. www.kbv.de/8156.html. Date last accessed: March 21, 2012.
6. Institut für das Entgeltsystem im Krankenhaus. Definitions Handbuch 2011. G-DRG Version 2011. Siegburg, InEK, 2011.
7. InEK - Institut für das Entgeltsystem im Krankenhaus. Datenveröffentlichung gem. § 21 KHEntgG: www.g-drg.de/cms/content/ view/full/2877. Date last accessed: March 21, 2012.
8. Gesundheitsberichterstattung des Bundes. Arbeitsunfähigkeit bei AOK - Pflichtmitgliedern ohne Rentner (Arbeitsunfahigkeitsfälle und Arbeitsunfahigkeitstage), 2008.
9. Schaberg T, Bauer T, Castell S, et al. [Recommendations for therapy, chemoprevention and chemoprophylaxis of tuberculosis in adults and children. German Central Committee against Tuberculosis (DZK), German Respiratory Society (DGP)]. Pneumologie 2012; 66: 133-171.
10. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
11. EuroTB (CESES/KNCV) and the national coordinators for tuberculosis surveillance in the WHO European Region (1998). Surveillance of tuberculosis in Europe Report on tuberculosis cases notified in 1996. http://ecdc.europa.eu/en/ publications/Publications/SUR-TB-EuroTB-EuroTB-Annual-report-1996.pdf Date last accessed: May 15, 2012.
12. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis, Emergency Update 2008 (WHO/HTM/TB/2008.402). Geneva, Switzerland.
13. Zierski M. Pharmakologie, Toxikologie und Anwendung von Pyrazinamid [Pharmacology, toxicology and clinical use of pyrazinamide]. Prax Klin Pneumol 1981; 35: 1075-1105. (Pubitemid 12251044)
14. Zierski M, Rotermund C. Isoniazid - Wesentliches und Neues. Prax Klin Pneumol 1984; 38: 201-216.
15. Schlossberg D. Current therapy of infectious disease. 2nd Edn. Mosby, St. Louis, 2001; pp. 565.
16. Diel R, Nienhaus A, Lange C, et al. Cost-optimization of screening for latent tuberculosis in close contacts. Eur Respir J 2006; 28: 35-44. (Pubitemid 44914258)
17. Graf von der Schulenburg JM, Greiner W, Jost F, et al. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health 2008; 11: 539-544. (Pubitemid 352032814)
18. Statistisches Bundesamt. Volkswirtschaftliche Gesamtrechnungen; Fachserie 18, Reihe 1.2 2. Vierteljahr 2011, 2.15 Arbeitnehmerengelt je Arbeitnehmer. Wiesbaden, Germany, 2011.
19. Statistisches Bundesamt: Ergebnisse des Mikrozensus: Jahresdurchschnittswerte.
20. Diel R. Schwierigkeiten und Schwachpunkte der TB-Kontrolle in Deutschland. 51. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin, Hannover, Germany, 2010.
21. Verband Deutscher Rentenversicherungsträger-VDR Statistik Rehabilitation. Durchschnittliche Pflegetage bei stationären Behandlungen zur medizinischen Rehabilitation und sonstigen Leistungen zur Teilhabe für Erwachsene in der Gesetzlichen Rentenversicherung (Anzahl).
22. Clade H. Rehabilitation: Steigender Bedarf, moderates Wachstum. Rheinisches Ärzteblatt 2010; 64: 23-25.
23. Statistisches Bundesamt, Bonn (2011). Todesursachen in Deutschland 2009. Fachserie 12 Reihe 4: 2.1 Sterbefälle 2009 nach ausgewählten Todesursachen, Altersgruppen und Geschlecht.
24. Diel R, Schneider S, Meywald-Walter K, et al. Epidemiology of tuberculosis in Hamburg, Germany: long-term population-based analysis in applying classical and molecular epidemiological techniques. J Clin Microbiol 2002; 40: 532-539. (Pubitemid 34130878)
25. Diel R, Niemann S. Outcome of tuberculosis treatment in Hamburg: a survey 1997-2001. Int J Tuberc Lung Dis 2003; 7: 124-131. (Pubitemid 36172672)
26. Hanson K. Measuring Up: Gender, Burden of Disease, and Priority Setting Techniques in the Health Sector. Working Paper Series 99. 12, Harvard Center for Population and Development Studies, Cambridge, 1999.
27. Atun RA, Samyshkin Y, Drobniewski F, et al. Costs and outcomes of tuberculosis control in the Russian Federation: retrospective cohort analysis. Health Policy Plan 2006; 21: 353-364. (Pubitemid 44594422)
28. Mancuso JD, Niebuhr DW, Frick KD, et al. Cost-Effectiveness analysis of targeted and sequential screening strategies for latent tuberculosis. Int J Tuberc Lung Dis 2011; 15: 1223-1330.
29. Schwarzmann K, Oxlade O, Barr RG, et al. Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med 2005; 353: 1008-1020. (Pubitemid 41262335)
30. Holland DP, Sanders GD, Hamilton CD, et al. Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. PLoS One 2011; 6: e22276.
31. Porco TC, Lewis B, Marseille E, et al. Cost-effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrants. BMC Public Health 2006; 6: 157.
32. Diel R, Wrighton-Smith P, Zellweger JP. Cost-effectiveness of interferon-c release assay testing for the treatment of latent tuberculosis. Eur Respir J 2007; 30: 321-332. (Pubitemid 47194185)
33. Pooran A, Booth H, Miller RF, et al. Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulm Med 2010; 10: 7.
34. Kowada A, Deshpande GA, Takahashi O, et al. Cost effectiveness of interferon-gamma release assay versus chest X-ray for tuberculosis screening of BCG-vaccinated elderly populations. Mol Diagn Ther 2010; 14: 229-236.
35. World Health Organization. Tuberculosis country profiles. www.who.int/entity/tb/country/data/profiles/en/index.html Date last accessed: March 21, 2012.
36. Konietzko N, Fabel H. Weibbuch Lunge 2005. 3. Revised edition. Stuttgart, Thieme, 2005.
37. Blaas SH, Muetterlein R, Weig J, et al. Extensively drug-resistant tuberculosis in a high-income country: a report of four unrelated cases. BMC Infect Dis 2008; 8: 60.
38. Eker B, Ortmann J, Migliori GB, et al. Multidrug- and extensively drug resistant tuberculosis, Germany. Emerg Infect Dis 2008; 14: 1700-1706.